Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Methods for Prevention and Treatment of Polyomavirus Infection or Reactivation (E-179-2007)

Posted Jun 13 2010 5:00pm

Description of Invention:
Available for licensing and commercial development are methods of using Tranilast [N-(3',4'-dimethoxycinnamoyl)anthranilic acid] in the prevention and treatment of human polyomavirus infection. Treatment with Tranilast decreases viral protein expression for two human polyomavirus species, JC virus (JCV) and BK virus (BKV). Furthermore, the increase in JCV/BKV protein production observed upon the addition of TGF-beta could also be effectively abolished by Tranilast co-treatment. This is of relevance because TGF-beta has previously been demonstrated to increase during immunosuppressive conditions, including HIV infection and kidney transplantation.

JCV is responsible for demyelization of the central nervous system, which is observed in cases of progressive multifocal leukoencephalopathy (PML). PML is most frequently seen in patients with HIV/AIDS, but is also a contributing factor in fatalities in patients with leukemia, lymphoma, and connective tissue diseases, in addition to individuals receiving immunosuppressive therapy for autoimmune disorders or prevention of transplant rejection. BKV is associated with serious clinical syndromes such as viruria and viremia, ureteral ulceration and stenosis, and hemorrhagic cystitis and has a causative role in polyomavirus-associated nephrophathy in as many as 10% of all renal transplant recipients. Currently, there are no effective antiviral agents available to treat these opportunistic infections. In all observed cases, activation of either JCV or BKV in immunosuppressed patients has resulted in fatalities.

Applications:
Use in treatment and prevention of polyomavirus infection in immunocompromised patients. Specific target is the prevention of PML in treatment therapies for MS patients.

Development Status:
In vitro data is currently available and inventors are actively developing the technology.

Inventors:
Veerasamy Ravichandran (NINDS)
Eugene O Major (NINDS)
Jeffrey B Kopp (NIDDK)


Licensing Status:
Available for non-exclusive or exclusive licensing.

Collaborative Research Opportunity:
The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize treatment and prevention of polyomavirus infections in immunocompromised patients, with particular interest in JCV and demyelination. Please contact Melissa Maderia, Ph.D., at maderiam@mail.nih.gov for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Therapeutics
In-vitro Data



For Additional Information Please Contact:
Cristina Thalhammer-Reyero Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 33,
Rockville, MD 20852
United States
Email: thalhamc@mail.nih.gov
Phone: 301-435-4507
Fax: 301-402-0220


Ref No: 1606

Updated: 06/2010

Post a comment
Write a comment:

Related Searches